Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITTen: Mesna, Ifosfamide, Teniposide, Taxol in Relapsed Lymphoma
NCT00004916Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Feb 1999
- Primary completion
- Oct 2002
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teniposide in non-Hodgkin lymphoma (NHL), sponsored by Northwestern University. Primary endpoints: Toxicities associated with the combination and Maximum Tolerated Dose of Teniposide. Started Feb 1999; status: completed.
02
Drugs
teniposide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00004916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004916.